Review
Copyright ©The Author(s) 2015.
World J Hepatol. Mar 27, 2015; 7(3): 304-314
Published online Mar 27, 2015. doi: 10.4254/wjh.v7.i3.304
Table 1 Important risk factors for spontaneous bacterial peritonitis
Variceal bleeding[15]
Previous SBP[6]
Genetic polymorphisms in the NOD2[55,56], TLR2[61], MCP1[62,63] and FXR[54] gene
Low ascites protein content (below 1-1.5 g/dL)[7]
Advanced liver disease[116]
Intake of proton pump inhibitors[96,97]
Table 2 Randomised controlled trials concerning antibiotic treatment of spontaneous bacterial peritonitis
Ref.No. of patientsStudy armsResolution of infectionPComment
Felisart et al[117]73Ampicillin + tobramycin vs cefotaxime56% vs 85%< 0.02Also patients without SBP included
Rimola et al[118]143Cefotaxime 8 g/24 h vs 4 g/24 h77% vs 79%NS
Navasa et al[119]123Ofloxacin po vs cefotaxime iv84% vs 85%NSOnly patients with uncomplicated SBP included
Ricart et al[120]48Amoxicillin-clavulanic acid vs cefotaxime88% vs 83%NS
Terg et al[121]80Ciprofloxacin only iv vs 2 d iv then po76 vs 78%NS
Piano et al[86] (NCT01455246) (preliminary results presented at the AASLD 2014, Abstract 574)32Daptomycin + meropenem vs ceftazidime87% vs 25%< 0.001Only patients with nosocomial SBP included
Table 3 Randomised controlled trials concerning antibiotic prophylaxis of spontaneous bacterial peritonitis
Ref.No. of patientsStudy armsKind of prophylaxisOccurence of SBPP
Ginés et al[93]80Norfloxacin vs placeboSecondary12% vs 35%0.014
Soriano et al[122]63Norfloxacin vs controlPrimary/secondary0% vs 23%< 0.05
Singh et al[123]60Trimethoprim-sulfamethoxazole vs controlPrimary/secondary3% vs 27%0.025
Grangé et al[124]107Norfloxacin vs placeboPrimary0% vs 9%NS
Rolachon et al[125]60Ciprofloxacin vs placeboPrimary/secondary4% vs 22%< 0.05
Novella et al[126]109Norfloxacin permanently vs only during hospitalisationPrimary2% vs 17%< 0.01
Fernández et al[92]68Norfloxacin vs placeboPrimary7% vs 61%< 0.001
Terg et al[127]100Ciprofloxacin vs placeboPrimary4% vs 14%0.076